ArbiLayer
CLAW logo

IP Tokens of IPNFT #129

CLAW Rank #5598
$0.1129▼ 7.77%24h
Low $0.1112High $0.1226

Price chart

Loading price history…
Market cap$124.1KRank #5598
Fully diluted value$124.1K
Volume (24h)$697.70Vol / Mcap 0.56%
Circulating supply1.10MCLAW
Total supply1.10M
Max supply∞no hard cap
All-time high$1.10Aug 24, 2025
All-time low$0.0875Jun 30, 2026

What is IP Tokens of IPNFT #129?

Overview

Percepta is a patent-protected dietary supplement containing PTI-00703 Cat's claw and MemorTea, a specific oolong extract, designed to address cognitive decline and neurodegenerative diseases. The project operates within the decentralized science framework, targeting the brain health supplement market while pursuing clinical validation and regulatory pathways. CLAW represents a tokenization of the underlying patent portfolio supporting the supplement's development and related research initiatives.

How it works

CLAW is deployed on the Base blockchain network. The token structure enables participation in a crowdsale mechanism for funding clinical evidence studies that could support advanced regulatory status, including potential FDA botanical drug designation.

Token and supply

Total supply is fixed at approximately 1.1 million CLAW tokens with no maximum supply constraint listed. The token is traded on Aerodrome and Uniswap V3, both on Base.

Where to trade CLAW

2 exchanges · top 10

All 2 markets
#ExchangePairsVolume (24h)
1Aerodrome (Base) logoAerodrome (Base)Spot DEXCLAW / WETH$76.72Trade ↗
2Uniswap V3 (Base) logoUniswap V3 (Base)Spot DEXBIO / CLAW$75.85Trade ↗
Live spot quotes from connected exchanges
VenueBidAskMidStatus
Open to load live quotes.

CLAW funding rates

Live perpetual funding on every connected exchange. Positive = longs pay shorts.

Full view

Contracts & chains

Exact contract or mint per network — the identity layer used for DEX routing.

Resolving token registry…

On-chain routes

Networks with a connected DEX routing adapter.

Loading DEX coverage…

IP Tokens of IPNFT #129 news

All news
Loading related headlines…